Loading...
•
Dec 31, 2025
West Pharma Q4 2025 Earnings Report
West Pharmaceutical Services reported strong fourth-quarter 2025 results, driven by double-digit organic revenue growth in HVP Components.
Key Takeaways
West Pharmaceutical Services, Inc. announced strong fourth-quarter and full-year 2025 financial results. The company's fourth-quarter net sales increased by 7.5% to $805.0 million, with organic growth of 3.3%. Diluted EPS grew by 2.2% to $1.82, while Adjusted-diluted EPS increased by 12.1% to $2.04. The Proprietary Products Segment, particularly High-Value Product Components, was a key driver of this performance.
Fourth-quarter net sales increased by 7.5% to $805.0 million, with organic growth of 3.3%.
Fourth-quarter Adjusted-diluted EPS rose by 12.1% to $2.04.
High-Value Product Components net sales increased by 20.3%, with 15.1% organic growth, driven by Westar® and Envision® products.
Full-year 2026 net sales are projected to be between $3.215 billion and $3.275 billion, with organic growth of approximately 5% to 7%.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
For the full year 2026, West Pharmaceutical Services expects net sales to be in the range of $3.215 billion to $3.275 billion, assuming a mid-year close for the sale of SmartDose 3.5ml to AbbVie. Organic net sales growth is projected to be approximately 5% to 7%. Adjusted-diluted EPS is expected to be between $7.85 and $8.20, representing growth of 7.7% to 12.5%. First-quarter 2026 net sales are anticipated to be between $770 million and $790 million, with adjusted-diluted EPS between $1.65 and $1.70.
Positive Outlook
- Full-year 2026 reported net sales growth expected between 4.6% and 6.5%.
- Full-year 2026 organic net sales growth expected between 5% and 7%.
- Full-year 2026 adjusted-diluted EPS growth expected between 7.7% and 12.5%.
- First-quarter 2026 reported net sales growth expected between 10.3% and 13.2%.
- First-quarter 2026 adjusted-diluted EPS growth expected between 13.0% and 16.4%.
Challenges Ahead
- The sale of SmartDose® 3.5mL to AbbVie, which generated $55 million in revenues in the second half of 2025, will impact reported net sales.
- The guidance assumes a mid-year 2026 close for the SmartDose 3.5ml sale, which could introduce uncertainty.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...